Table 3.

Inclusion and exclusion criteria

Inclusion criteria	• Women with recurrent miscarriage and/or intra-uterine fetal deaths (that is ≥ two miscarriages of intra-uterine fetal deaths, irrespective of gestational age)
	• Confirmed inherited thrombophiliaa
	◦ factor V Leiden mutation
	◦ prothrombin gene mutation (G20210A)
	◦ protein S deficiency
	◦ protein C deficiency
	◦ antithrombin deficiency
	• Pregnancy confirmed by urine pregnancy test
	• Age 18 to 42 years at randomization
	• Willing and able to give informed consent
Exclusion criteria	• Duration of current pregnancy ≥ 7 weeks, based on first day of last menstruation
	• Indication for anticoagulant treatment during pregnancy (e.g., prosthetic heart valves, a history of venous thromboembolism or antiphospholipid syndrome)
	• Contraindications to LMWH (previous heparin-induced thrombocytopenia, active bleeding or renal insufficiency with creatinine clearance of < 30 ml/minute)
	• Known allergy to at least three different LMWH preparations
	• Previous inclusion in the ALIFE2 study (for another pregnancy)

^aProtein S, protein C and antithrombin deficiencies need to be confirmed by two tests, performed on two separate occasions and not during anticoagulant therapy. Protein S tests should not be performed during pregnancy or in the 6-week post-partum period since spuriously low levels may then be observed.